HISUN(SH:600267) 艾瑞咨询·2026-01-13 00:05Core Viewpoint - The article highlights the recognition of Zhejiang Haizheng Animal Health Products Co., Ltd. as the leading player in the Chinese pet medicine market, with its product Hailuwang being the top-selling dog deworming product nationwide [1][15][16]. Company Overview - Zhejiang Haizheng Animal Health Products Co., Ltd. is a subsidiary of Zhejiang Haizheng Pharmaceutical Co., Ltd. (stock code: 600267), which has invested 800 million RMB to build an international animal health enterprise [4]. - The company operates two major production bases in Fuyang and Kunming, producing a wide range of products including injections, tablets, and various vaccines [5]. Product Details - Hailuwang is a specialized dog deworming product available in multiple packaging specifications, primarily containing Milbemycin Oxime and Praziquantel, effective against various common parasites [7]. - The product is designed for dogs over 2 weeks old and weighing more than 0.5 kg, featuring a palatable beef flavor [7]. Competitive Advantages - Haizheng Animal Health's rapid growth is attributed to its parent company's pharmaceutical expertise and stringent quality control across the entire production chain [9]. - The company emphasizes six core competitive advantages: 1. Pure raw materials with low impurity levels [9]. 2. Lean R&D leveraging the parent company's strong capabilities [10]. 3. International production lines adhering to high-quality standards [10]. 4. Rigorous quality control throughout the production process [10]. 5. Multiple international certifications including GMP and ISO [10]. 6. Commitment to high-quality, stable products that align with green principles [10]. Industry Development - The Chinese pet medicine industry has evolved from reliance on imported products to a phase of independent innovation, with significant growth in domestic brands since 2010 [11][12]. - The market for dog deworming products has transitioned from basic availability to a more sophisticated supply, reflecting the rise of domestic brands and a shift towards preventive health care [13]. Market Position - Haizheng Animal Health's sales are projected to reach approximately 500 million RMB from 2024 to October 2025, confirming its position as the top-selling domestic pet medicine brand [15]. - The Hailuwang product has achieved over 6.03 million units sold from 2020 to October 2025, establishing it as the leading dog deworming product in the domestic market [16]. Industry Ecosystem - The production and distribution systems for domestic pet medicines are becoming increasingly sophisticated, with companies enhancing quality control and supply chain management [14]. - The industry is moving towards a more regulated and diversified development model, supported by ongoing improvements in regulatory frameworks and digital upgrades in pet healthcare [14].